These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18724156)

  • 21. Cell viability score (CVS) as a good indicator of critical concentration of benzalkonium chloride for toxicity in cultured ocular surface cell lines.
    Iwasawa A; Ayaki M; Niwano Y
    Regul Toxicol Pharmacol; 2013 Jul; 66(2):177-83. PubMed ID: 23557985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
    Wagner RS; Abelson MB; Shapiro A; Torkildsen G
    Arch Ophthalmol; 2005 Sep; 123(9):1282-3. PubMed ID: 16157821
    [No Abstract]   [Full Text] [Related]  

  • 23. [Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro].
    Li J; Yan XM
    Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):43-50. PubMed ID: 20388322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo toxicity of netilmicin and ofloxacin on intact and mechanically damaged eyes of rabbit.
    Marino C; Paladino GM; Scuderi AC; Trombetta F; Mugridge K; Enea V
    Cornea; 2005 Aug; 24(6):710-6. PubMed ID: 16015091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model.
    Liang H; Baudouin C; Daull P; Garrigue JS; Brignole-Baudouin F
    Mol Vis; 2012; 18():2195-204. PubMed ID: 22919267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of resveratrol on protecting corneal epithelial cells from cytotoxicity caused by moxifloxacin and benzalkonium chloride.
    Tsai TY; Chen TC; Wang IJ; Yeh CY; Su MJ; Chen RH; Tsai TH; Hu FR
    Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1575-84. PubMed ID: 25670486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of uridine on cornea in a rabbit dry eye model.
    Oh JY; In YS; Kim MK; Ko JH; Lee HJ; Shin KC; Lee SM; Wee WR; Lee JH; Park M
    Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1102-9. PubMed ID: 17325152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of comet assays under conditions mimicking ocular instillation administration in a three-dimensional reconstructed human corneal epithelial model.
    Tahara H; Sadamoto K; Yamagiwa Y; Nemoto S; Kurata M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):375-383. PubMed ID: 31223032
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model.
    Barequet IS; Habot-Wilner Z; Lavinsky F; Ziv H; Belkin M; Rosner M
    Cornea; 2007 Jun; 26(5):606-9. PubMed ID: 17525660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracameral moxifloxacin: in vitro safety on human ocular cells.
    Kernt M; Neubauer AS; Liegl RG; Lackerbauer CA; Eibl KH; Alge CS; Ulbig MW; A AK
    Cornea; 2009 Jun; 28(5):553-61. PubMed ID: 19421040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro comparison of the cytotoxic effects of clinically available ophthalmic solutions of fluoroquinolones on human keratocytes.
    Mencucci R; Paladini I; Pellegrini-Giampietro DE; Menchini U; Scartabelli T
    Can J Ophthalmol; 2011 Dec; 46(6):513-20. PubMed ID: 22153639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols.
    Herrygers LA; Noecker RJ; Lane LC; Levine JM
    Cornea; 2005 Jan; 24(1):66-71. PubMed ID: 15604869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy.
    Burka JM; Bower KS; Vanroekel RC; Stutzman RD; Kuzmowych CP; Howard RS
    Am J Ophthalmol; 2005 Jul; 140(1):83-7. PubMed ID: 15953577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
    Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
    Kim SJ; Toma HS
    Ophthalmology; 2011 Jul; 118(7):1358-63. PubMed ID: 21420176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications for Ophthalmic Formulations: Ocular Buffers Show Varied Cytotoxic Impact on Human Corneal-Limbal and Human Conjunctival Epithelial Cells.
    Schuerer N; Stein E; Inic-Kanada A; Pucher M; Hohenadl C; Bintner N; Ghasemian E; Montanaro J; Barisani-Asenbauer T
    Cornea; 2017 Jun; 36(6):712-718. PubMed ID: 28399036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.
    Pellinen P; Huhtala A; Tolonen A; Lokkila J; Mäenpää J; Uusitalo H
    Curr Eye Res; 2012 Feb; 37(2):145-54. PubMed ID: 22049909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.
    Solomon R; Donnenfeld ED; Perry HD; Snyder RW; Nedrud C; Stein J; Bloom A
    Ophthalmology; 2005 Mar; 112(3):466-9. PubMed ID: 15745775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.